Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

134 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Italian guidelines on the systemic treatments of moderate-to-severe plaque psoriasis.
Gisondi P, Altomare G, Ayala F, Bardazzi F, Bianchi L, Chiricozzi A, Costanzo A, Conti A, Dapavo P, De Simone C, Foti C, Naldi L, Offidani A, Parodi A, Piaserico S, Prignano F, Rongioletti F, Stingeni L, Talamonti M, Girolomoni G. Gisondi P, et al. Among authors: dapavo p. J Eur Acad Dermatol Venereol. 2017 May;31(5):774-790. doi: 10.1111/jdv.14114. Epub 2017 Feb 27. J Eur Acad Dermatol Venereol. 2017. PMID: 28244153
Consensus on the management of patients with psoriatic arthritis in a dermatology setting.
Gisondi P, Altomare G, Ayala F, Conti A, Dapavo P, De Simone C, Foti C, Idolazzi L, Lubrano E, Malara G, Marchesoni A, Olivieri I, Parodi A, Peris K, Piaserico S, Salvarani C, Scarpa R, Girolomoni G. Gisondi P, et al. Among authors: dapavo p. J Eur Acad Dermatol Venereol. 2018 Apr;32(4):515-528. doi: 10.1111/jdv.14741. Epub 2018 Jan 11. J Eur Acad Dermatol Venereol. 2018. PMID: 29220551
Predictors of response to omalizumab and relapse in chronic spontaneous urticaria: a study of 470 patients.
Marzano AV, Genovese G, Casazza G, Fierro MT, Dapavo P, Crimi N, Ferrucci S, Pepe P, Liberati S, Pigatto PD, Offidani A, Martina E, Girolomoni G, Rovaris M, Foti C, Stingeni L, Cristaudo A, Canonica GW, Nettis E, Asero R. Marzano AV, et al. Among authors: dapavo p. J Eur Acad Dermatol Venereol. 2019 May;33(5):918-924. doi: 10.1111/jdv.15350. Epub 2018 Dec 7. J Eur Acad Dermatol Venereol. 2019. PMID: 30451325 Free article.
Secukinumab drug survival in patients with psoriasis: A multicenter, real-world, retrospective study.
Torres T, Balato A, Conrad C, Conti A, Dapavo P, Ferreira P, Gaiani F, Leite L, Malagoli P, Mendes-Bastos P, Megna M, Messina F, Nidegger A, Odorici G, Piaserico S, Prignano F, Ribero S, Ricceri F, Tonini A, Valério J, Chiricozzi A. Torres T, et al. Among authors: dapavo p. J Am Acad Dermatol. 2019 Jul;81(1):273-275. doi: 10.1016/j.jaad.2019.02.031. Epub 2019 Feb 18. J Am Acad Dermatol. 2019. PMID: 30790602 No abstract available.
Secukinumab shows high efficacy irrespective of HLA-Cw6 status in patients with moderate-to-severe plaque-type psoriasis: results from extension phase of the SUPREME study.
Papini M, Cusano F, Romanelli M, Burlando M, Stinco G, Girolomoni G, Peris K, Potenza C, Offidani A, Bartezaghi M, Aloisi E, Costanzo A; SUPREME study group. Papini M, et al. Br J Dermatol. 2019 Aug;181(2):413-414. doi: 10.1111/bjd.18013. Epub 2019 May 29. Br J Dermatol. 2019. PMID: 31001812 Clinical Trial. No abstract available.
Secukinumab demonstrates improvements in absolute and relative psoriasis area severity indices in moderate-to-severe plaque psoriasis: results from a European, multicentric, retrospective, real-world study.
Chiricozzi A, Balato A, Conrad C, Conti A, Dapavo P, Ferreira P, Gaiani FM, Leite L, Malagoli P, Mendes-Bastos P, Megna M, Messina F, Nidegger A, Odorici G, Panduri S, Piaserico S, Piscitelli L, Prignano F, Ribero S, Valerio J, Torres T. Chiricozzi A, et al. Among authors: dapavo p. J Dermatolog Treat. 2020 Aug;31(5):476-483. doi: 10.1080/09546634.2019.1671577. Epub 2019 Oct 2. J Dermatolog Treat. 2020. PMID: 31557063 Clinical Trial.
134 results